<i>Letter to the Editor:</i> Remission of Graves' Disease After Initiation of Ocrelizumab in Patients with Multiple Sclerosis-Reference-Cited by-同舟云学术

Letter to the Editor: Remission of Graves' Disease After Initiation of Ocrelizumab in Patients with Multiple Sclerosis

Published:2023-02-01 Issue:2 Volume:33 Page:267-269
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Casany-Fernandez Rosa¹,Gascon-Gimenez Francisco²,Matarredona Solaz Enrique Juan¹,Pardo Lozano Felipe¹,Dominguez-Moran Jose Andres²,Ferri Ciscar Jordi¹,Real Collado Jose Tomas¹³⁴

Affiliation:

1. Department of Endocrinology and Nutrition, Hospital Clinico Universitario de Valencia, Valencia, Spain.

2. Multiple Sclerosis Unit, Department of Neurology, Hospital Clinico Universitario de Valencia, Valencia, Spain.

3. INCLIVA (Instituto de Investigacion Sanitaria), Valencia, Spain.

4. CIBERDEM (Centro de investigación biomedica en red de diabetes y enfermedades metabólicas asociadas), Madrid, Spain.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2022.0398

Reference5 articles.

1. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response

2. Thyroid autoimmunity and dysfunction associated with type I interferon therapy

3. Graves’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference center

4. Post-alemtuzumab Graves’ disease remitting after switch to ocrelizumab

5. New Therapeutic Horizons for Graves’ Hyperthyroidism

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alemtuzumab induces severe orbitopathy in relapsing–remitting multiple sclerosis;Journal of Neurology;2023-09-29

2. Alemtuzumab/interferon-β;Reactions Weekly;2023-07-22

3. Non-thionamide antithyroid drug options in Graves’ hyperthyroidism;Expert Review of Endocrinology & Metabolism;2023-01-02